Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study

BACKGROUND: The efficacy of benralizumab has been broadly demonstrated in severe eosinophilic asthma (SEA), but only few real-life studies evaluated its long-term effects. Here we present novel data from the ANANKE study in which a large cohort of SEA patients was treated for up to 96 weeks. METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales: Vultaggio, Alessandra, Aliani, Maria, Altieri, Elena, Bracciale, Pietro, Brussino, Luisa, Caiaffa, Maria Filomena, Cameli, Paolo, Canonica, Giorgio Walter, Caruso, Cristiano, Centanni, Stefano, D’Amato, Maria, De Michele, Fausto, Del Giacco, Stefano, Di Marco, Fabiano, Menzella, Francesco, Pelaia, Girolamo, Rogliani, Paola, Romagnoli, Micaela, Schino, Pietro, Senna, Gianenrico, Benci, Marco, Boarino, Silvia, Schroeder, Jan Walter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10200058/
https://www.ncbi.nlm.nih.gov/pubmed/37210543
http://dx.doi.org/10.1186/s12931-023-02439-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10200058/
https://www.ncbi.nlm.nih.gov/pubmed/37210543
http://dx.doi.org/10.1186/s12931-023-02439-w

Ejemplares similares